Journal of Jilin University Medicine Edition ›› 2016, Vol. 42 ›› Issue (04): 817-820.doi: 10.13481/j.1671-587x.20160435

Previous Articles     Next Articles

Primary bone marrow diffuse large B-cell lymphoma: One case report and literature review

ZHANG Wenlong1, YANG Hua2, SUN Yanxia1   

  1. 1. Department of Hematology and Oncology, China-Japan Union Hospital, Jilin University, Changchun 130033, China;
    2. Department of Pathology, China-Japan Union Hospital, Jilin University, Changchun 130033, China
  • Received:2015-11-05 Published:2016-07-20

Abstract:

Objective: To analyze the diagnosis and treatment of 1 case of primary bone marrow diffuse large B cell lymphoma (DLBCL), and to provide the reference for its dignosis and treatment. Methods: Combined the medical history and other auxiliary examination results, the possibility of diagnosis of primary bone marrow lymphoma(PBML) was suspected. Bone marrow biopsy and immunohistochemistry were carried out for diagnosis, and R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) was selected as the chemotherapy scheme. Results: The diagnostic basis of the case was in accordance with the diagnostic standard of PBML. According to the results of immunohistochemical staining, it was classified as the DLBCL subtype. Then the patient received 6 cycles of R-CHOP immune chemotherapy. Complete remission of bone marrow cell morphology was gained after the first cycle of R-CHOP treatment, and the patient was treated for another five cycles and the complete remission was retained in 3 months of follow up after drug withdrawal. Conclusion: Bone marrow biospy and immunohistochemistry have the unique diagnostic values for primary bone marrow DLBCL, and the regimens containing rituximab may provide a ideal efficacy during short term observation.

Key words: primary bone marrow lymphoma, diffuse large B cell lymphoma, bone marrow biopsy

CLC Number: 

  • R733.4